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Abstract 
Objective: We assessed the ability of two commercially-available fractions labeled SX and D 
derived from the edible maitake mushroom to overcome many age-associated metabolic 
perturbations such as progressive, age-related elevation of blood pressure, over activity of the 
renin-angiotensin system (RAS), decreased insulin sensitivity, and inflammation in an in vivo 
laboratory model. 
Design and Method: We divided forty mature, female Sprague-Dawley rats (SD) into five 
groups of eight. SD ingested regular rat chow containing added sucrose (20% w/w). The 
groups received baseline diet alone (control) or baseline diet containing captopril, nia-
cin-bound chromium, maitake fraction SX, or maitake fraction D. In addition to blood 
pressure readings, the following procedures were implemented: losartan and insulin chal-
lenges, evaluation of serum ACE activity, glucose tolerance testing, blood chemistries, 
LNAME challenge, and measurement of various circulating cytokines. 
Results: We found that implementation of all test conditions stopped the gradual elevation of 
systolic blood pressure (SBP) in the SD over the four months of study, even reversing some of 
the previous elevation that occurred over time. In general, the treatment groups showed 
decreased activity of the RAS estimated by less lowering of SBP after losartan challenge and 
decreased serum ACE activity and were more sensitive to exogenous insulin challenge. TNFa 
levels decreased in all four test groups suggesting a lessening of the inflammatory state. 
Conclusions: We believe our data suggest that maitake mushroom fractions lessen 
age-related hypertension, at least in part, via effects on the RAS; enhance insulin sensitivity; 
and reduce some aspects of inflammation -- actions that should lead to a longer, healthier life 
span. 
Key words: Age-related hypertension, Sugar-induced hypertension, Maitake mushroom, 
age-related hypertension, Maitake, insulin sensitivity, inflammation 
INTRODUCTION 
It is generally believed that diet influences many 
deleterious, age-related, chronic changes in human 
health [1-3]. To give well-studied examples of these 




carbohydrates (CHO) like sucrose and fructose by 
certain strains of rats have been linked to systolic 
blood pressure (SBP) elevations [4,5], insulin resis-
tance [6], and many inflammatory perturbations [7]. 
Accordingly, safe, easy-to-implement, and effective 
dietary means to prevent, lessen or even overcome 
harmful, chronic health disorders via inhibition of 
these age-related metabolic disturbances would be 
welcomed.  
The present study examines in a rodent model 
the potential for two commercially available fractions 
labeled SX and D derived from the edible maitake 
mushroom to overcome many age-associated meta-
bolic perturbations such as the progressive elevation 
of blood pressure (BP) and disordered glucose meta-
bolism. Previous studies have found that whole 
powder and crude fractions of the mushroom might 
do so [8-13]. As a secondary gain, the influences of SX 
and D on the renin-angiotensin system (RAS), insulin 
sensitivity, and inflammation were also examined. 
 
MATERIAL AND METHODS 
Protocol: 
  The Animal Welfare Board at Georgetown Uni-
versity Medical Center approved the protocol for this 
investigation. Forty mature female Sprague-Dawley 
rats (SD), obtained from Taconic Farms, Germantown, 
NY, were used. The present studies were carried out 
on SD near one year in age (338 days). The SD, 
weighing between 280-378 g at the beginning of the 
studies, were housed in a constant temperature room 
with a light-dark phase of 12 hours each. The SD rats 
were divided into five groups, each containing eight 
rats. All rats ate a basic diet of ground regular rat 
chow containing sucrose (20% w/w). The control 
group received only the basic diet, while the other 
four groups each received the basic diet containing on 
a weight basis: captopril, (30 mg/Kg) niacin-bound 
chromium [NBC] (8.6 mg/Kg), Maitake Fraction D 
(350 mg/Kg) or Maitake Fraction SX (3500 mg/Kg). 
Based on weight and metabolic considerations for the 
rat [14], the doses of NBC, fractions D and SX roughly 
approximate effective human doses as suggested by 
the supplier for these natural ingredients. 
Maitake D Fraction is a standardized extract 
from maitake mushroom that contains as it active 
ingredient a protein-bound beta-glucan that is a po-
werful enhancer of the immune system through oral 
administration [15]. The water-soluble fraction of 
powdered whole Maitake mushroom designated 
SX-fraction is a glycoprotein with an average mole-
cular weight of 20,000 Daltons that is extracted from 
maitake mushroom through a proprietary process 
developed by Maitake Products, Inc.
1 [15]. Both mu-
shroom extracts were the generous gift of Mushroom 
Wisdom, Inc. (East Rutherford, NJ).  
The SHR were followed for 120 days while con-
suming their respective diets. Body weights and sys-
tolic blood pressure (SBP) were routinely measured. 
During the last two weeks of the study, specialized 
tests [glucose-tolerance (GTT), insulin-challenge 
(ICT), losartan challenge, and L-Name challenge] 
along with blood chemistry assessments were carried 
out. 
Body Weight (BW):  
  BW was estimated by routine scale measure-
ments. Two reading taken at least 10 minutes apart on 
the given day had to be within two grams of each 
other or the procedure was repeated until the weights 
were consistently within the two gram range. 
Food and Water Intake: 
  Water and food intakes were estimated close to 
the mid point of the study by subtracting the volume 
or weight of the remaining fluid and food from the 
amounts premeasured 24 hours earlier. 
Blood Pressure (BP):  
  Systolic blood pressure (SBP) was measured by 
tail plethysmography [16] using two different in-
struments. As in many of our previous studies and for 
the majority of our measurements, we used an in-
strument from Narco Biosciences (Houston, TX) [4,5]. 
This allowed us to rapidly measure SBP with a beeper 
sound system. The second reading was performed on 
an instrument obtained from Kent Scientific Corpora-
tion (Torrington, CT). This is a computerized, 
non-invasive tail cuff acquisition system that utilizes a 
specially designed differential pressure transducer to 
non-invasively measure the blood volume in the tail. 
The latter instrument not only allowed us to record 
SBP, but also diastolic BP (DBP), mean BP (MBP), and 
cardiac rate. A previous report showed that the SBP 
readings were essentially similar between the two 
instruments [17]. Rats were allowed free access to 
their diet and water until SBP and the other cardi-
ovascular readings were obtained after a slight 
warming between 13.00 h and 17.00 h. Multiple 
readings on individual rats at each reading were tak-
en. To be accepted, SBP measurements on a given rat 
had to be virtually stable. Over the course of study, 
multiple readings were recorded.  
                                                      




Blood Chemistries:  
Blood for chemical analysis was obtained at the 
end of the chronic protocol following removal of food 
the night before. Chemistry data were obtained via 
dry chemistry procedures using a Johnson and John-
son Vitros 250 instrument. 
ipGTT:  
During the ipGTT, glucose (2.5 g/Kg BW) was 
injected intraperitoneally (i.p.) to challenge the toler-
ance to glucose. Drops of blood were obtained from 
the rat tail at 0, 15, 30, 60, and 120 minutes post injec-
tion. Glucose was estimated using commercial glu-
cose strips (Lifescan, One Touch Ultra, Melitas, CA). 
Insulin measurements were made at baseline and one 
hour into the testing. Statistical comparisons were 
made by differences in area under the curve (AUC) 
over the two hours of study. 
Insulin Challenge Testing (ICT):  
Testing was commenced after 17-19 hours of 
food deprivation. For ICT, 0.6 unit of regular insu-
lin/kg BW (Eli Lilly Co., Indianapolis, IN) and glu-
cose 250 mg/Kg were administered intraperitoneally 
(i.p.). Blood for glucose determinations was obtained 
from the tail vein at 7.5 minutes after injection. Glu-
cose was estimated using commercial glucose strips 
(Lifescan, One Touch Ultra, Melitas, CA). 
Losartan Challenge:  
After performing baseline SBP readings, SHR 
from all dietary groups were given 20 mg/kg losartan 
orally via gastric lavage [18]. Three and six hours after 
lavage, SBP was remeasured. The decreased SBP after 
losartan was used to estimate activity of the RAS with 
a greater decrease in SBP connoting augmented sys-
tem activity [19]. 
Serum ACE Activity:  
ACE refers to the angiotensin converting en-
zyme. Serum ACE activity was measured by a com-
mercial kit (Sigma Co. Ltd, St. Louis, MO) [20]. This 
spectrophotometric method utilizes the synthetic tri-
peptide substrate N-[3-(2-furyl)acryloyl]-- 
phenylalanylglcylglcine (FAPGG). FAPGG is hydro-
lyzed by ACE to furylacryloylphenylalanine (FAP) 
and glycylglycine. Hydrolysis of FAPGG results in a 
decreased absorbency at 340 nm. Serum ACE activity 
was determined by comparing the sample reaction 
rate to that obtained with an appropriate ACE cali-
brator. 
LNAME Challenge: 
  Effects of nitric oxide synthase (NOS) inhibition 
on SBP were measured [19]. After baseline measure-
ments of SBP, the NOS inhibitor Nw-nitro-L argi-
nine-methyl ester hydrochloride (LNAME) was given 
intraperitoneally (i.p.) at a dose of 10 mg/kg. Each rat 
received a single dose of LNAME. Measurements of 
SBP were taken at four, seven, 10, 15, and 20 minutes 
post injection. The area under the curve was used to 
estimate activity of the NO system with an increase in 
SBP connoting augmented system activity. 
Cytokine Assay: 
Various cytokines were measured by ELISA 
methodology using kits from the following sources: 
rat MCP-1 - Assay Designs Inc., Ann Arbor, MI; rat 
adiponectin - ALPCO Diagnostics, Salem, NH; TNF-a, 
ALPCO Diagnostics, Salem, NH; RAT IL-1B - Assay 
Designs Inc, Ann Arbor; Rat IL-6 - ALPCO Diagnos-
tics, Salem, NH. 
Statistical Analyses: 
Results are presented as mean + SEM. SBP and 
BW were examined by repeated measures, 2-way 
analyses of variance (one factor being group and the 
second factor being time of examination). Where a 
significant effect of regimen was detected by ANOVA 
(p<0.05), the Dunnett t test was used to establish 
which differences between means reached statistical 
significance [21]. When the data from two columns 
were analyzed at a single time point, Student’s t test 
was used. Statistical significance was set at a p < 0.05. 
A trend is defined as p <0.1>0.05. 
RESULTS 
Body Weight (Fig.1): 
  There was a steady decrease in average body 
weight over the four months of study in these mature 
female SD (Fig. 1). Examining the overall data over 
the course of study shows that the changes in weight 
were reasonably similar in all groups during the 
study. 
Food and Water Intake (Table 1):  
The food and water intakes near the mid point of 
study are depicted in Table 1. There were no signifi-
cant differences in the 24 food consumption, and wa-
ter intake was similar in all groups with the exception 
of the SD taking captopril in their food. These rats had 
a lower average water intake.  
Blood Chemistries (Table 2): 
 Tail blood was obtained at the end of study, and 
in general, the various blood chemistries among 
groups were similar. The only statistically significant 
differences were in the circulating creatinine levels. 




SX were statistically significantly elevated 
and those of the SD ingesting nia-
cin-bound chromium trended upward 
compared to control. Similar changes 
were not seen in BUN concentrations. 
Although the fasting blood sugar (FBS) 
levels averaged lower in the chromium 
and maitake groups, these values did not 
attain statistical significance. 
 
Figure 1. Body weight (BW) of SD in Con-
trol, Captopril, Chromium, Fraction D and 
Fraction SX groups over the course of study. 











Table 1. Food and Water Intake - Day 50 
Food Intake (g/24h) 
Cont Captopril Chromium  Fraction D  Fraction SX 
16.5±0.5 15.8±0.3  18.5±0.6  17.4±0.8  17.4±0.7 
        
Water Intake (ml/24h) 
Cont Captopril Chromium  Fraction D  Fraction SX 
21.9±0.7 18.8±0.6*  20.0±1.0  20.7±1.1  22.1±0.9 
Average ± SEM shown  
*Statistically different from control 
Table 2. BLOOD CHEMISTRIES  
Parameter Control  Captopril  Cr  Frac D   Frac SX 
FBS (mg/dl) 118.1±4.8  117.0±3.2  113.3±3.1  113.8±5.6 106.9±3.2 
Insulin (ng/ml) 0.79±003  0.70±0.04  0.74±0.06  0.71±0.03 0.76±0.05 
BUN (mg/dl) 16.4±0.8  18.1±0.5  16.4±0.9  16.9±1.2  17.1±0.7 
Cr (mg/dl) 0.5±.02  0.6±.03  0.7±.06  0.8±.09*   0.8±.08* 
Na (mEq/L) 140±0.5  139±0.7  139±0.5  141±0.4  141±0.5 
Cl (mEq/L) 100±1.0  101±0.5  100±0.7  101±0.5  101±0.8 
CO2 (mEq/L) 26±0.5  27±0.6  26±0.6  24±0.4  26±0.8 
Ca (mEq/L) 10.8±0.1  10.9±0.1  11.2±0.2  10.8±0.1  10.8±0.2 
Cholesterol (mg/dl) 133±5.0  131±3.8  131±3.4   125±4.3  130±5.0  
Triglycerides (mg/dl) 176±9.4  167±7.5  187±8.5   171±9.5  171±10.8 
AST (units) 112±19.1  111±8.8  110±3.2   107±7.4  119±8.6 
ALT (units) 78±9.6  91±8.2  89±0.4   81±8.3   94±7.2 
Alk Phos (units) 87±4.3  97±5.9  88±6.3  102±4.8  104±5.0 
Mean ± SEM for each group of 6-7 rats is depicted, *= statistically significantly different from control (p<0.05) 
 





Blood Pressure (Fig. 2,3, Table 3): 
  Although this study was initiated on day 338 in 
the life of the female SD, the SBP of all 40 SD ingesting 
the control diet containing 20% sucrose had been rec-
orded previously -- starting on day 50 of life up to that 
point in time (Fig, 2). From day 338 on, only the SBP of 
the group that continued as Control 0(n=8) is de-
picted. Of note, throughout their recorded lifespan, 
the SBP of the female SD consuming only diet gener-
ally increased, i.e., the gradual rise followed for more 
than one year was about 25 mm Hg.  
  The average SBP readings of the control group 
rose steadily over the four months of the present 
study – day 338 to day 464 (Fig. 2,3). In Fig. 3, Day 338 
is listed as 0. In contrast, the average SBP of the 
groups receiving chromium, fraction D, or fraction SX 
decreased significantly after 10 days on their respec-
tive diets and remained at fairly consistent levels (Fig, 
3). Those SD in the captopril group showed no sig-
nificant decrease at 10 days but a significant lowering 
of average SBP by day 30 and throughout the re-
mainder of the study. 
The entire BP profile and heart rate were as-
sessed near the end of the study as shown in Table 3. 
Measured by another method, the SBP remained sig-
nificantly lower in all test groups compared to control, 
with the lowest average readings in the captopril 
group. Likewise, the average diastolic (DBP) and 
mean BP (MBP) were significantly lower in the test 
groups compared to control. There were no significant 
differences in the cardiac rate among groups. 
Intraperitoneal Glucose Tolerance Test (ipGTT)(Table 4) 
 The area under the curve (AUC) for the 2 
hour-long ipGTT was lowest in the Maitake SX group, 
but not statistically significantly different. No signifi-
cant differences among the five groups were seen in 




Figure 2. Systolic blood pressure (SBP) of SD rats under Control conditions over a period of 458 days (n=8). The present 
study began on Day 338 of their lifespan. The start of the present study is indicated by * below the initial baseline reading. 





Figure 3. Systolic blood pressure (SBP) of SD in Control, Captopril, Chromium (Cr) and Fraction D (D) and Fraction SX 
(SX) groups over a period of 120 days. n=8 in each group. Data are expressed as mean ± SEM. 
 
Table 3 Cardiovascular Readings at 4 Months 
Parameter Control  Captopril  Chromium  D Fractiom   SX Fraction 
SBP (mm Hg) 157±1.7  135±1.4*  142±1.6*  142±1.3*  141±1.2* 
DBP (mm Hg)   119±1.2   98±1.5*  111±1.2*  103±2.0*  109±0.9* 
MBP (mm Hg) 123±2.7  104±1.0*  113±2.2*  113±1.9*  111±1.4* 
Cardiac Rate   369±11.1  368±9.1  385±11.3  355±7.9  367±8.7 
Average ± SEM of 6-7 rats is shown 
* Statistically significant compared to control 
Table 4 Glucose Tolerance Test (Intraperitoneal) 
Group Glucose  (AUC-2h) Baseline  Insulin  (ng/ml)   1h Insulin (ng/ml) 
Control 12,226±967  0.79±0.06    2.14±0.09 
Captopril 11,987±1,063  0.68±0.06    2.08±0.16 
Chromium 11,420±971  0.77±0.06    2.05±0.18 
Maitake D  11,645±798  0.74±0.03   2.24±0.14 
Maitake SX   9,575±897  0.81±0.06   2.21±0.13 
Average ± SEM is shown for 6-7 SD. 
None of the values are significantly different from control. 
 
 
Insulin Challenge Test (ICT) (Fig. 4): 
  Both the control and treatment groups were 
challenged with intraperitoneal (i.p.) glucose and 
regular insulin. Seven and one-half minutes after the 
combined challenges with insulin and glucose, the 
levels of circulating glucose were as follows: control 
173 mg/dl + 7.5 (SEM); captopril 155 mg/dl + 9.2 
(SEM), niacin-bound chromium (NBC) 142 mg/dl + 
6.7 (SEM); Fraction D 133.3 mg/dl + 7.2 (SEM); and 
Fraction SX 138.8 mg/dl + 6.3 (SEM). Compared to 




different in the niacin-bound chromium, Fraction D 
and Fraction SX groups. The values in the captopril 
group showed a trend. 
Renin-Angiotensin System (RAS)(Fig. 5,6): 
  SD challenged with losartan showed a decrease 
in SBP (Fig. 5). Over the six hours of study, the aver-
age decrease from baseline in the control group was 
-42.0 mm Hg + 2.5 (SEM) that was statistically greater 
than all the test groups: captopril group -19 mm Hg + 
1.9 (SEM), niacin-bound chromium -28.5 mm Hg + 2.5 
(SEM), fraction D -34.0 mm Hg + 1.0 (SEM), and frac-
tion SX -24 mm Hg + 1.9 (SEM). Estimating ACE ac-
tivity, it was found that the activity was statistically 
lower than control in the captopril, fraction D, and 
fraction SX groups and the lessened activity trended 
toward significance in niacin-bound chromium group 
(Fig.6). 
Effect of LNAME on SBP (Fig 7) 
LNAME was injected into the SD to estimate NO 
activity [16]. After 30 minutes, there was a statistically 
significant increased area under the curve (AUC) for 
all four test groups compared to control.  
Cytokines (Table 5) 
TNF-a levels were statistically lower in all the 
test groups: captopril, niacin-bound chromium, Frac-
tion D, and Fraction SX compared to control. IL-6 was 
not significantly lower in any of the test groups. 
IL-1b-a, MCP-1, and adiponectin concentrations were 
not significantly different in any test group compared 
to control.  
Table 5 CYTOKINES and HORMONES  
Parameter Control    Captopril Chromium  Fraction D  Fraction SX  p 
TNF-a  413 ± 13.5  327 ± 13.1*  357 ± 13.9*  361±14.0*  351±13.4* <0.01 
IL-6  455 ± 12.5  432 ± 11.8  445 ± 9.5  441±13.9  441±16.0   0.91 
IL-1b-a  451 ± 13.8  407 ± 25.7  429 ± 14.3  433±20.7  426±11.5 0.62 
MCP-1  117 ± 4.4  101 ± 5.4  112 ± 5.5  113±5.1  107±2.7   0.32 
Adiponectin  5.05 ± 0.23  4.21 ± 0.25  4.88 ± 0.21  4.60±0.21  4.39±0.15 0.15 
Ave ± SEM of 8 rats. 
Units for TNFa, IL-6, IL-1b-a, and MCP-1 are pg/ml 
Unit for Adiponectin is ng/ml. 
* Statistical significance compared to control (p<0.05) 
# Trend toward statistical significance (>0.05<0.10) 
 
 
Figure 4. Elevation of circulating glucose level above 
baseline 7.5 minutes after i.p. injection of regular 
insulin and glucose. The elevations are significantly less 
in the Chromium (Cr) and Maitake D and SX groups 
signified by the symbol * compared to Control. A 
trend compared to Control is seen in the Captopril 
group (#). n=8 in each group. Data are expressed as 





Figure 5. Decrease in SBP from baseline over 6 hours after oral challenge with losartan. All test groups were statistically 
significantly different from control after 6 hours. n=8 in each group. Data are expressed as mean ± SEM. 
 
Figure 6. Circulating Angiotensin Converting Enzyme (ACE) Activity among various groups. A trend (#) for a lowering 
compared to Control was seen in the Chromium group (Cr). While the other three test groups were significantly lower 





Figure 7. Response to L NAME challenge among various groups. Increase in SBP from baseline over 30 minutes after i.p. 
challenge with L NAME. All test groups were significantly different from control over 30 minutes. n=8 in each group. Data 




Hypertension, an important preventable major 
risk factor for cardiovascular diseases and strokes that 
becomes more prevalent with aging, commonly oc-
curs after age 30 years [22]. Many believe that dietary 
macronutrients, especially refined CHO like sugars, 
play a significant role in age-related BP elevation 
[1,2,4]. Although Wotecke et al [23] estimate that total 
CHO consumption has fallen from 56% to 46% of 
energy intake over the first 75 years of the 21st cen-
tury, this has been wholly at the expense of complex 
CHO, because the consumption of refined CHO, es-
pecially sucrose and fructose, rose steadily to exceed 
20% of the energy intake. With the popularity of soft 
drink consumption, intake of sucrose and fructose has 
even become greater over the last few years [24]. 
Could this dietary change be related to the prevalence 
of hypertension [25]? 
  Sprague-Dawley rats (SD) are considered a 
normotensive strain of rats. Prior to beginning the 
present study, however, we fortuitously found that 
female SD consuming a regular diet containing added 
sucrose showed a gradual rise in the systolic blood 
pressure (SBP) from normotensive levels to hyperten-
sive levels over a long term (>150 mm Hg). Use of the 
female gender is important because of lesser informa-
tion on females who have a particularly difficult time 
with age-related hypertension [2,22]. Sucrose was 
added in the present investigation to assure that the 
regular feed of the SD contained a virtually similar 
portion of refined CHO calories as the normal Amer-
ican Diet [24] and may have been responsible for the 
hypertensive range of SBP in the SD [4-6]. Suffice it to 
say, this BP pattern in SD simulates in many ways the 
age-related hypertension often noted in humans [22].  
The pathological mechanism(s) behind the 
gradually rising, chronic BP elevation associated with 
refined CHO ingestion and/or aging is uncertain, 
because the elevated SBP may relate to a number of 
perturbed underlying regulating mechanisms that 
include augmented catecholamine levels [26], dis-
turbed vasodilatory function via disturbances in NO 
signaling in blood vessels [27], alterations in fluid and 
electrolyte balance [28], and disturbances in the re-
nin-angiotensin system (RAS) manifested by elevated 
circulating levels of angiotensin-2 [29].  The associa-
tion between the RAS and sugar-induced hyperten-
sion is especially intriguing, because, in addition to 




rious effect of circulating angiotensin-2 on the cardi-
ovascular system [30]. This may explain, at least in 
part, a previous finding that high consumption of 
sugars, shown to increase circulating levels of angi-
otensin 2 [29], can be associated with vascular lesions 
[31]. The ability of captopril to lower the elevated BP 
produced by sugar ingestion also corroborates the 
important role of the RAS in sugar-induced hyper-
tension. Niacin-bound chromium (NBC) has also been 
shown to lower the activity of the renin-angiotensin 
system and was, along with captopril, added as a 
positive control in these experiments [17]. In the 
present study, both NBC and captopril decreased 
blood pressure and lessened the activity of the RAS. 
In previous investigations, whole maitake mu-
shroom and crude fractions of the mushroom were 
shown to favorably affect hypertension and glu-
cose-insulin metabolism in rodents [9-13]. The crude 
fractions included a water extract and an ether extract, 
and the two rat species examined were genetically 
hypertensive rats (spontaneously hypertensive rats 
[SHR]) and genetically insulin-resistant rats (Zucker 
Fatty Rats [ZFR]). Different results were found in each 
species. At 35 days, only consumption of the diet 
containing the ether fraction significantly decreased 
systolic blood pressure (SBP) in SHR (average 197 vs. 
176 mm Hg, p <. 001), while in ZFR only the groups 
consuming the whole maitake and water extract 
showed significantly decreased SBP (138 vs. 120-125 
mm Hg, p <. 001). Even though the RAS could have 
played a role in the BP effects of the mushroom and its 
extracts on the SHR, a losartan challenge test in ZFR 
suggested that angiotensin 2 did not play a major role 
in SBP regulation under the conditions examined.  
In the present investigation, female SD rats 
showed gradually, but steadily, increasing SBP as 
they aged. Similar to the groups consuming captopril 
or niacin-bound chromium, SBP decreased signifi-
cantly early on indicating that both SX and D could 
halt and even reverse to some extent the sug-
ar-induced/age-related elevations of SBP (Figs. 2,3). 
By the end of the four months after introduction of the 
maitake fractions into the diet, the diastolic and mean 
BP were also significantly reduced compared to con-
trol. In the face of no significant differences in body 
weight and food and fluid intake suggesting that the 
test rats were receiving the tested substances in the 
proportions desired, the SBP changed markedly un-
der all test conditions, with the captopril addition 
bringing the SBP virtually to the same SBP as months 
earlier – reversing all the age-related elevations. With 
a single exception, i.e., the rise in creatinine with the 
maitake fractions, blood chemistries revealed no sig-
nificant toxic changes to go along with other evidence, 
i.e., no changes in appetite or body weight. We 
attribute the rise in creatinine levels in those SD con-
suming fractions SX and D to changes in muscle mass 
secondary to the status of insulin sensitivity and not 
to any problems with renal function, since the BUN 
levels were similar among groups. An insu-
lin-sensitizing agent like niacin-bound chromium has 
previously been associated with enhanced muscle 
build up [32]. Examining a panel of cytokines, all the 
test groups showed significantly lower levels of cir-
culating Tumor Necrosis Factor-alpha (TNF-α) sug-
gesting some anti-inflammatory capabilities (Table 5).  
Two tests to assess the activity of the RAS sug-
gest that decreased activity occurred when Fraction 
SX and all test groups were compared to control. The 
greater decrease in SBP after losartan challenge in the 
control group suggests that the RAS was more active 
in the control group compared to the SX group (Fig.5) 
[19,33]. When estimating the ACE activity in the se-
rum of the SD [34], the latter was found to be lower in 
the captopril, fraction D and Fraction SX group com-
pared to control. The NBC group showed a trend to-
ward decreased activity relative to control. Previous 
in vitro work pointed out the ACE inhibitory effects of 
mushrooms [35]. 
Kopilas et al 27] examined sugar-induced BP 
elevations in SHR and concluded that the NO system 
was significantly involved in the pathogenesis. We 
examined the ability of LNAME, a substance that can 
inhibit the dilatory actions of NO, to influence SBP 
and found a trend toward raised BP, more so in all the 
test groups. Accordingly, this supports the contention 
that a relatively depressed NO system is involved in 
sugar-induced hypertension [27] and that captopril, 
chromium, and fractions D and SX can enhance this 
system causing lower SBP. 
  Based upon previous findings, addition of Mai-
take SX to the diet of sucrose-eating rats would be 
expected to enhance insulin sensitivity, and we be-
lieve that to be the case here [11,13]. In the present 
study carried out on normotensive, female Spra-
gue-Dawley rats, the circulating levels of fasting 
blood glucose (Table 2) and the area under the curve 
in a glucose tolerance test (Table 4), tended to be less, 
although not significantly so. More to the point, 
however, the challenge test to estimate insulin sensi-
tivity did show a statistically improved activity in the 
SD ingesting fraction SX. Captopril and NBC were 
examined at the same time to act as positive controls. 
Ace inhibitor agents, like captopril, have been re-
ported to have insulin-sensitizing abilities [36-39] and 
could theoretically reduce inflammation [40,41], and 
this proved to be the case here. Captopril showed a 




previously shown to enhance insulin sensitivity, also 
did likewise. Somewhat surprising was the finding 
that Fraction D enhanced insulin sensitivity. It is not 
clear why this happened. Fraction D is known pri-
marily for its immune enhancing properties [15]. It is 
unclear if the same substance or a difference sub-
stance in SX and D is responsible for the enhancement 
of insulin sensitivity and the inhibition of RAS.  
To summarize some major points emanating 
from the present study, two commercial extracts of 
maitake mushroom (SX and D) are safe natural 
products that can favorably influence the progressive 
elevation of SBP over time, enhance insulin sensitivi-
ty, and lower circulating levels of a cytokine asso-
ciated with inflammation – TNF-α. Accordingly, this 
makes the maitake mushroom and its commercial 
extracts excellent candidates to produce a long, 
healthful life span [42]. 
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